NCT02589821View on ClinicalTrials.gov

Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors

PHASE3CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

December 7, 2015

Primary Completion Date

November 11, 2019

Study Completion Date

July 7, 2022

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Surufatinib

Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

OTHER

Placebo

Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Trial Locations (5)

100032

Peking Union Medical College Hospital, Beijing

100071

the 307 Hospital of People's Liberation Army, Beijing

100142

Beijing Cancer Hospital, Beijing

510060

Sun Yat-sen University Cancer Center, Guangzhou

610047

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02589821 - Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter